Development of fragment-based Hepatitis C (HCV) viral replication inhibitors (360G-Wellcome-087738_Z_08_A)
Development of fragment-based Hepatitis C (HCV) viral replication inhibitorsAn estimated 170 million people worldwide are infected with HCV with treatment requiring an extended period of therapy and influenced by side effects and low response rates.The Trust has provided £2 million programme related investment to Cambridge based Astex Therapeutics to use their proprietary fragment-based screening approach, Pyramid (TM), to identify and develop novel inhibitors which bind to newly identified regulatory site on a HCV viral protein. Such novel agents would be of significant value in a disease where combination therapy is vital to limiting the emergence of viral resistance.
Where is this data from?
This data was originally published by The Wellcome Trust. If you see something about your organisation or the funding it has received on this page that doesn't look right you can submit a grantee amendment request. You can hover over codes from standard codelists to see the user-friendly name provided by 360Giving.
Grant Details
| Amount Awarded | 1000000 |
| Applicant Surname | Thompson |
| Approval Committee | Seeding Drug Discovery Committee |
| Award Date | 2010-07-21T00:00:00+00:00 |
| Financial Year | 2009/10 |
| Grant Programme: Title | Seeding Drug Discovery Award |
| Internal ID | 087738/Z/08/A |
| Lead Applicant | Dr Neil Thompson |
| Partnership Value | 1000000 |
| Planned Dates: End Date | 2010-12-31T00:00:00+00:00 |
| Planned Dates: Start Date | 2009-01-01T00:00:00+00:00 |
| Recipient Org: Country | United Kingdom |
| Region | East of England |